Vincerx Pharma, Inc. Common Stock
VINC
VINC was delisted on the 22nd of April, 2025.
42 hedge funds and large institutions have $18.6M invested in Vincerx Pharma, Inc. Common Stock in 2022 Q3 according to their latest regulatory filings, with 5 funds opening new positions, 8 increasing their positions, 13 reducing their positions, and 14 closing their positions.
1% more capital invested
Capital invested by funds: $18.4M → $18.6M (+$166K)
18% less funds holding
Funds holding: 51 → 42 (-9)
38% less repeat investments, than reductions
Existing positions increased: 8 | Existing positions reduced: 13
64% less first-time investments, than exits
New positions opened: 5 | Existing positions closed: 14
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RSCM
Rock Springs Capital Management
Baltimore,
Maryland
|
+$423K |
| 2 |
Russell Investments Group
London,
United Kingdom
|
+$297K |
| 3 |
SSA
Schonfeld Strategic Advisors
New York
|
+$269K |
| 4 |
AAA
Affinity Asset Advisors
New York
|
+$171K |
| 5 |
ECM
ExodusPoint Capital Management
New York
|
+$104K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
LFCM
Long Focus Capital Management
San Juan,
Puerto Rico
|
-$1.41M |
| 2 |
PVI
Pura Vida Investments
New York
|
-$143K |
| 3 |
Millennium Management
New York
|
-$142K |
| 4 |
SFM
Sphera Funds Management
Tel Aviv,
Israel
|
-$93K |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
-$82.4K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
51
Wells Fargo
San Francisco,
California
| – | +$29 | +1 | +20% |
|
VINC Hedge Fund Activity: Q3 2022 in Review
42 of the 5,806 institutional investors tracked by Wall St. Rank reported a position in Vincerx Pharma, Inc. Common Stock (VINC) for Q3 2022, worth a combined $18.6M — up 0.9% from $18.4M a quarter earlier.
Sellers outnumbered buyers: 14 funds closed out of VINC and 5 opened new positions — a net loss of 9 holders — while 13 trimmed existing stakes and 8 added.
The largest buyer was Rock Springs Capital Management, adding an estimated $423K. The largest seller was Long Focus Capital Management, exiting entirely with an estimated $1.41M sold.
- 42 institutional investors held Vincerx Pharma, Inc. Common Stock (VINC) as of Q3 2022, down from 51 in Q2 2022.
- Funds reported $18.6M of Vincerx Pharma, Inc. Common Stock stock for Q3 2022, up 0.9% quarter-over-quarter.
- 5 funds opened new Vincerx Pharma, Inc. Common Stock positions in Q3 2022 and 14 closed out, a net change of -9 holders.
- The largest Vincerx Pharma, Inc. Common Stock buyer in Q3 2022 was Rock Springs Capital Management, an estimated $423K added.
- The largest Vincerx Pharma, Inc. Common Stock seller in Q3 2022 was Long Focus Capital Management, an estimated $1.41M sold.
Based on aggregated 13F filings for Q3 2022.